Pharmadule returns to China Pharm with ‘industry first’ case study
Press Release | Pharmadule Morimatsu AB
OCTOBER 21, 2014
Nacka, Stockholm: – Swedish-based designer and builder of modular production facilities for the pharma and biopharma industries, Pharmadule Morimatsu AB (Pharmadule) will consolidate its rising profile within the rapidly expanding Asian pharma market with a prominent presence and exhibition at the forthcoming 19th China International Pharmaceutical Industry Exhibition, CHINA-PHARM 2014.
The exhibition, which has become a premier event for the Asian life sciences sector, is being held from October 28 to October 31 in Shenzhen’s ultra-modern SZCEC Expo Center.
Pioneering validation in China
On the eve of the show, Pharmadule will partner with fellow Swedish-based company, Alfa Laval, the heat transfer, separation and fluid-handling specialists, to host a full day pre-show event at the Sheraton Four Points hotel.
One of the highlights of the event will be a presentation by Pharmadule Morimatsu Director for Regulatory Affairs, Magnus Jahnsson, on ‘Qualifying a manufacturing facility in China to comply with EU and US GMP guidelines’.
Mr. Jahnsson said: “I’ll be presenting a case study in which a new Chinese facility for a biopharmaceutical product has been built and qualified with state-of-the-art risk management methods to US and EU standards. So far as we are aware, this is a ‘first’ for the pharma industry.”
“To do this, we’ve had to overcome a series of technical and cultural challenges that our audience will understand all too well,” he added.
Growing regulatory trend
“Previously very few pharmaceutical manufacturers in China have aimed to launch their products in EU or the US. Only API manufacturers have been exporting internationally,” explained Mr. Jahnsson.
“But now we will undoubtedly see more Chinese companies seeking to register their products internationally over the coming years. This presentation will facilitate a better understanding of the unique challenges and the many opportunities that this export drive will bring,” he concluded.
Mr. Jahnsson will make a similar presentation the following day at China-Pharm itself.
This will be Pharmadule’s seventh appearance at CHINA-PHARM, and the company is sending a multi-disciplinary team to this premier Asian networking and partnering event. The team will be able to provide details of Pharmadule’s offerings, including turnkey design and construction services, modular off-site production solutions, commissioning and qualification expertise, GMP and ISO 9000 consultancy and extended after-sales services.
The company will also be using the exhibition’s networking opportunities to identify forthcoming project leads and partners.
About Pharmadule Morimatsu
Pharmadule Morimatsu designs and builds turnkey production facilities for the pharma and biopharma Industries. Pharmadule engineering and design services extend from conceptual design to IQ/OQ completion, offering a one-stop-shop suite of services that include: Front-End Design & Pre-Engineering, Detailed Design, Fabrication, Quality Assurance and Validation Management.
Pharmadule also offers regulatory and GMP consultancy and validation management services.
The company was founded in 1986, since when it has successfully delivered more than 70 projects worldwide for clients including Eli Lilly, Merck, Baxter, GlaxoSmithKline, Genentechand AstraZeneca, forging The Pharmadule Way as a way of offering unique value and reassurance to customers, with off-site construction and modular design concepts to provide very high predictability of on time, on budget delivery and consistent high quality, regardless of final location.
Pharmadule is part of the Morimatsu Group of Japan, forming Pharmadule Morimatsu AB, headquartered in Stockholm, Sweden. The company also has a strong presence in the USA and Asia with engineering and manufacturing facilities in Shanghai, providing an enhanced service for clients in new markets.
About CHINA-PHARM 2014
The China International Pharmaceutical Industry Exhibition & China International Pharmaceutical Industry Forum (CHINA-PHARM for short) has now become one of the foremost life sciences events in Asia with significant influence on the international pharmaceutical field.
The 19th China International Pharmaceutical Industry Exhibition will take place October 28-31 at the Shenzhen Conference and Exhibition Centre (SZCEC), having been staged in Shanghai in 2013.
Covering a space of around 30,000 m3, CHINA-PHARM 2014 will feature more than 500 leading Chinese and international brand exhibitors as well as an estimated 25,000 trade visitors, of whom some 3,000 will come from EMEA and the Americas.
CHINA-PHARM is hosted by the China Center for Pharmaceutical International Exchange (CCPIE), in partnership with Messe Düsseldorf China Ltd. (MDC). The latter was founded in 1999 as a joint venture between Messe Düsseldorf GmbH and World-Fair Consultants Ltd. to bring long-established German events to China.
More information at http://www.china-pharm.net/NewsType.aspx?id=55
Maria Rosén Davidsson, Marketing Director, Pharmadule Morimatsu AB
Tel: +46 (0)8 587 42 000
Click on Pharmadule returns to China Pharm with ‘industry first’ case study for more information.
Click on Pharmadule to contact the company directly.